This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

Two resulted in verdicts against the formula companies, totaling $495 million against Abbott Laboratories and $60 million ...

Investors happily greeted the latest news from Abbott Laboratories (NYSE: ABT) on Hump Day. After the storied healthcare company unveiled its third-quarter results, those folks traded its stock up ...

Abbott Laboratories beat third-quarter profit and sales estimates on strong demand for its medical devices. Sales were also higher at its pharmaceutical unit, but fell at its diagnostics and ...

The Department of Justice announced an investigation into Abbott Laboratories' Michigan plant which was at center of a nationwide formula shortage in 2022. Abbott is recalling several of its ready ...

Since my previous article, shares of Abbott Laboratories have returned 10% versus the 7% gains of the S&P 500 index. The healthcare company's sales and adjusted diluted EPS rose in the third quarter.

The Motley Fool has positions in and recommends Abbott Laboratories ... that we'll be launching and then other markets we're ...

Abbott Laboratories showcases robust financial performance with a notable increase in net earnings. Strategic acquisitions and product launches strengthen the company's market presence.

Is the company still worth a look if you're a long-term investor? Abbott Laboratories is one of the world's leading medical device makers. It routinely develops and markets newer products ...

Abbott Laboratories (NYSE:ABT) underwent analysis by 9 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. Summarizing their recent assessments, the table ...

Abbott Laboratories (NYSE:ABT ... optimism about Abbott's diversified business model and its ability to keep building on recent successes, with new product launches and strategic collaborations ...